Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Hydroxyurea
Drug ID BADD_D01110
Description An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Indications and Usage For management of melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary and Sickle-cell anemia.
Marketing Status approved
ATC Code L01XX05
DrugBank ID DB01005
KEGG ID D00341
MeSH ID D006918
PubChem ID 3657
TTD Drug ID D07CWD
NDC Product Code 0904-6939; 35369-0006; 49452-3650; 55154-7143; 61269-403; 68084-284; 70518-3615; 51927-0072; 0555-0882; 55154-3554; 69315-164; 38779-1354; 42291-321; 71770-105; 49884-724; 17337-0023; 0003-6335; 0003-6337; 60429-265; 61269-835; 70518-0916; 55512-0003; 61269-402; 71770-120; 0003-0830; 51552-0851; 62049-135; 0003-6336; 61269-404; 10135-702; 71052-323; 17337-0022
UNII X6Q56QN5QC
Synonyms Hydroxyurea | Hydroxycarbamid | Oncocarbide | Hydrea
Chemical Information
Molecular Formula CH4N2O2
CAS Registry Number 127-07-1
SMILES C(=O)(N)NO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Central nervous system lymphoma18.04.04.013; 17.02.10.028; 16.20.01.005; 01.12.01.0050.000112%Not Available
Concomitant disease aggravated08.01.03.0630.000280%Not Available
Hypergammaglobulinaemia benign monoclonal16.23.01.004; 01.14.01.0040.000112%Not Available
Metastases to lymph nodes16.22.02.006; 01.09.01.0150.000112%Not Available
Normal newborn18.08.06.0010.000302%Not Available
Scleroderma-like reaction10.04.07.005; 23.03.02.019; 15.06.01.0180.000112%Not Available
Splenic haematoma24.07.01.079; 01.09.02.014; 12.01.17.0190.000168%Not Available
Squamous cell carcinoma of the oral cavity07.21.07.009; 16.13.07.0060.000112%Not Available
Squamous cell carcinoma of the tongue16.13.07.007; 07.21.07.0100.000112%Not Available
Vitamin B1 deficiency14.12.02.0120.000381%Not Available
Concomitant disease progression08.01.03.0640.000112%Not Available
Live birth18.08.02.0070.000224%Not Available
Blast crisis in myelogenous leukaemia16.01.08.002; 01.10.08.0020.000112%Not Available
Gastric antral vascular ectasia24.03.03.028; 07.15.04.0030.000112%Not Available
Metastases to meninges17.02.10.012; 16.22.02.0030.000112%Not Available
Acute chest syndrome24.03.08.006; 22.06.03.004; 01.04.02.0040.000168%Not Available
Pachymeningitis17.06.03.0040.000112%Not Available
Breast cancer metastatic21.05.01.016; 16.10.01.0080.000112%Not Available
Gastric varices haemorrhage24.07.02.044; 09.01.06.014; 07.12.01.0050.000112%Not Available
Nephrogenic anaemia20.01.01.007; 01.03.04.0010.000112%Not Available
Thalamus haemorrhage24.07.04.033; 17.08.01.0620.000168%Not Available
Acute myeloid leukaemia recurrent16.01.05.004; 01.10.05.0040.000112%Not Available
Leukaemia recurrent16.01.03.005; 01.10.03.0050.000112%Not Available
Acute lymphocytic leukaemia recurrent01.10.01.003; 16.01.01.0030.000112%Not Available
Gastric fistula07.11.05.011; 12.02.03.0180.000112%
Internal haemorrhage24.07.01.0720.000112%Not Available
Primary myelofibrosis01.13.03.008; 16.21.03.0080.000504%Not Available
Acute erythroid leukaemia01.10.05.006; 16.01.05.0060.000168%Not Available
Acute megakaryocytic leukaemia16.01.05.007; 01.10.05.007--Not Available
Blood loss anaemia24.07.01.088; 01.03.02.0180.000168%Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene